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Background: This study examined the efficacy and safety of N-acetylcysteine (NAC) augmentation for treating
irritability in children and adolescents with autism spectrum disorders (ASD).
Method: Forty children and adolescents met diagnostic criteria for ASD according to DSM-IV. They were
randomly allocated into one of the two groups of NAC (1200 mg/day)+risperidone or placebo+risperidone. NAC
and placebo were administered in the form of effervescent and in two divided doses for 8 weeks. Irritability
subscale score of Aberrant Behavior Checklist (ABC) was considered as the main outcome measure. Adverse
effects were also checked.
Results: The mean score of irritability in the NAC+risperidone and placebo+risperidone groups at baseline was 13.2(5.3)
and 16.7(7.8), respectively. The scores after 8 weeks were 9.7(4.1) and 15.1(7.8), respectively. Repeated measures of ANOVA
showed that there was a significant difference between the two groups after 8 weeks. The most common adverse effects
in the NAC+risperidone group were constipation (16.1%), increased appetite (16.1%), fatigue (12.9%), nervousness (12.9%),
and daytime drowsiness (12.9%). There was no fatal adverse effect.
Conclusions: Risperidone plus NAC more than risperidone plus placebo decreased irritability in children and adolescents
with ASD. Meanwhile, it did not change the core symptoms of autism. Adverse effects were not common and NAC was
generally tolerated well.
Trial registration: This trial was registered at http://www.irct.ir. The registration number of this trial was
IRCT201106103930N6
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Autism spectrum disorders (ASD) are characterized by the
three main symptoms of: a) significant impairments in so-
cial relationships, b) language and communication deficits,
and c) restricted interests. Although, autistic disorders
are not very common, their current rates are higher than
that of the previously reported rates [1]. About 1.9% of
school aged children obtain screening cutoff score for
probable autistic disorder [2]. The rate for typical autism* Correspondence: ghanizad@sina.tums.ac.ir
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use, distribution, and reproduction in any medin five-year-old children is 6.26 per 10,000 [3]. In addition,
the global prevalence of autism spectrum disorders is
62/10 000 [4].
The neurobiology and etiology of autism are not clearly
known [5]. However, genetic [6], neurologic, metabolic,
and immunologic factors are suggested to be involved. It
is proposed that there is an imbalance of oxidative stress
and anti-oxidative defenses in children with autism [7,8].
The deficit in antioxidant system is specific in autism [9]
and it mediates the association of some behavioral symp-
toms and immunity function [10]. While plasma antioxi-
dant capacity is decreased [11], the plasma oxidative stress
indicators, such as nitric oxide (NO) and malondialdehyde
(MDA), are increased [12]. In addition, lipid peroxidation
is increased in autism [13]. Oxidative stress markers insee BioMed Central Ltd. This is an Open Access article distributed under the
icense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted
ium, provided the original work is properly cited.
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tients and some of them are suggested as the biomarkers
of autism [14]. The levels of superoxide dismutase (SOD)
and glutathione peroxidase, as antioxidant enzymes, are
lower in autism than that of the controls [15].
Oxidative stress negatively affects mitochondrion through
respiratory chain [16]. Therefore, oxidative stress is sug-
gested as a target for treating autism [7,17]. In addition,
animal models of autism revealed that targeting oxidative
markers was effective for treating autism [18].
Glutathione plays a significant role in defense against
oxidative stress in autism [7,19]. The level of glutathione
in the cerebellum and temporal cortex of patients with
autism are markedly decreased (34.2% and 44.6%, re-
spectively) [20]. The levels of both reduced glutathione
and total glutathione are lowered in autistic patients
than that of the controls [21]. Moreover, glutathione
pathway gene variation increases the risk of autistic dis-
orders [22].
Glutathione, which is the most important intracellular
defense against oxidative stress, consists of glutamate,
glycine, and cysteine [7]. The pathways of methionine
cycle, transsulfuration pathway, and GSH-synthesis path-
way produce glutathione [23]. The role of cysteine for
the production of glutathione is very important because
cysteine has a rate-limiting role [7]. Recently, an eight-week,
open-label trial showed that glutathione supplementation
increased the reduced-form of glutathione in plasma in
children with autism spectrum disorders [24]. This sup-
plementation also increased the plasma levels of sulfate,
cysteine, and taurine [24].
In addition, glutamate is involved in the pathophysi-
ology of autism [25] and glutamate blockers improve the
animal models of autism [26,27]. Some other interven-
tions targeting glutamate are suggested for treating autism
as well [28-30].
N-acetylcysteine (NAC) is an antioxidant precursor to
glutathione [31]. NAC restores GSH level [31]. In addition,
NAC scavenges oxidants such as hydroxyl radical and
H2O2 [32]. NAC improves glutamate homeostasis and de-
creases the relapse rate in drug-dependent patients [33].
NAC is an effective and safe agent for treating schizophre-
nia [34], bipolar disorder [35], Alzheimer’s disease [36], and
nail biting [37]. Moreover, the adverse effects of NAC are
mild and self-limited in children [38]. NAC is an over-the-
counter supplement.
About 75.5% of patients with autism respond to risper-
idone while the rate for placebo is 11.5% (effect size=1.2)
[39]. Aripiprazole with the effect size of 0.87 is effective
too [40]. This trial investigates the efficacy and safety
of NAC as an adjuvant treatment with risperidone for
treating the irritability of children with ASD. Consider-
ing the role of glutathione in autism and the effect of
NAC on glutathione level, it is hypothesized that NACas an augmentation agent decreases irritability score in
children with ASD.Methods
This study was an eight week randomized double-blind
placebo-controlled clinical trial with two parallel groups.
The patients, parents, and independent assessor were
blind to the allocation of patients. The patients were
randomly allocated into one of the two groups using a
random number generator.
The participants were a convenient sample of outpatients
children aged between 3.5 to 16 years old from both gen-
ders. The sample was recruited from the Child and Ado-
lescent Psychiatriy Clinics affiliated with Shiraz University
of Medical Sciences, Iran.
The diagnosis of autism was made using DSM-IV-TR cri-
teria. The diagnosis was in accordance with Autism Diag-
nostic Interview-Revised (ADI-R) [41]. All the interviews
were conducted by an expert child and adolescent psych-
iatrist (A.G.). Assessments were performed by a resident of
psychiatry trained to use the questionnaire and checklist.
The level of intelligence was not considered as an exclusion
criterion. However, the participants should be able to take
the medications.
The patients were free from any concomitant medica-
tion. Otherwise, the dose of medication should not be
markedly changed during two weeks prior entering into
this study. The dose of concomitant medication was not
markedly changed during this trial.
Patients with psychotic disorders, active substance abuse
or dependence, unstable medical condition, evidence of
active liver disease, seizure disorder, unstable hypertension
or cardiac disease, unstable asthma, and kidney disease as
determined by the investigator were not included. Taking
concomitant medications with glutamatergic effects (e.g.,
dextromethorphan, D-cycloserine, amantadine, memantine,
lamotrigine, riluzole) was not allowed. In addition, those
with hypersensitivity/allergy to NAC were not included.
One of the two groups received risperidone plus
N-Acetylcysteine (1200 mg/day). The patients received
1200 mg/day NAC in two divided doses. Both NAC and
placebo tablets were administered in the form of efferves-
cent. The other group received risperidone plus placebo
tablets. The shape, size, taste, and color of NAC and pla-
cebo were identical.
The dose was titrated up during two weeks. The dose
was not fixed. In addition, all the patients in both groups
received risperidone. Risperidone started at the dose of
0.5 mg/day and it was titrated up to 2 mg/day during
three weeks for children less than 30 kg. The dose for
children more than 30 kg was up to 3mg/day [42,43]. The
dose of risperidone was not fixed and it could be changed
considering the clinical symptoms and adverse effects.
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Checklist [44]. ABC consists of 58 items and includes
5 subscales. The subscales are Irritability, Lethargy and
Social Withdrawal, Stereotypic Behavior, Hyperactivity
and Noncompliance, and Inappropriate Speech.
The changes of Irritability subscale score was considered
as the main outcome of the current trial.
It was completed at pre-intervention, 4 weeks after the
beginning of intervention, and 8 weeks after the begin-
ning of intervention. In addition, the adverse effects and
extrapyramidal symptoms were systematically examined
and assessed using checklists [43]. The patients and their
parents were also asked regarding possible adverse effects.
This trial’s protocol and procedures were approved by
Ethics Committee of Shiraz University of Medical Sciences,
Iran. Then, this trial was registered at http://www.irct.ir. The
registration number of this trial was IRCT201106103930N6.
This trial was performed in 2011 and 2012. The parents
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Figure 1 Flow chart for the clinical trial N-Acetylcysteine + risperidonAnalysis
SPSS was used to perform statistical analyses. Chi-Square
test was used to compare the gender ratio between the
two groups. The mean of age was compared between
the two groups using independent t-test. Repeated Measures
of ANOVA was used to examine the effect of interven-
tions on the subscales scores of ABC. Intent-to-Treat
(ITT) using Last Observed Carried Forward (LOCF) with
at least one post-treatment evaluation was used to handle
missing data [45]. The Cohen’s d was calculated to meas-
ure effect size. P value less than 0.05 was set for being
statistically significant. This is an exploratory small
sample size trial.
Results
Out of 47 children who were screened, 40 patients were
randomized into one of two groups. The reasons for
the drop of patients in the two groups are displayed in
Figure 1. The number of boys in the NAC and placebo Seizure (n=5) 
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Figure 2 Comparison of irritability subscale scores between
N-Acetylcysteine + risperidone group and Placebo+Risperidone group.
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tistically significant difference between the two groups
regarding gender ratio (X2=.4, df=1, P=0.5). In addition,
the mean of age was not different between the two
groups (t=0.4, df=29, P=0.4). The mean age of children
in the NAC and placebo group was 8.8(3.1) and 7.9(2.4)
years, respectively. The list of concomitant medications
is presented in Table 1. The mean (SD) dose of risperi-
done in the NAC+risperidone and placebo+risperidone
groups was 0.76(0.2) mg/day and 0.92(0.3) mg/day, re-
spectively. It was not significantly different between the
two groups (t=1.4, df=29, P=0.1).
Repeated measures ANOVA showed both NAC and
Placebo decreased Irritability subscale score during the
trial (F1.4,43.0=10.5, P<0.001) (Figure 2). The irritability
scale score decreased from 13.2(5.3) to 9.7(4.1) in the
NAC+risperidone group. However, the irritability score
decreased 16.7(7.8) to 15.1(7.8) in the placebo+risperidone
group. Repeated measures ANOVA showed that the
effects of groups were significantly different (F1,29=4.9,
P<0.035). Moreover, the interactive effect of time and
group (time×group) was not statistically different (Table 2).
The pattern of changes for Irritability subscale score was
different between the NAC+risperidone and placebo+
risperidone groups. NAC+risperidone more than placebo+
risperidone decreased this score (effect size= .14). There
was no difference between the two groups regarding
Lethargy and Social Withdrawal, Stereotypic Behavior,
Hyperactivity and Noncompliance, and Inappropriate
Speech subscales scores.
Adverse effects
Adverse effects were also checked. None of the participants
experienced any fatal adverse effect. Only one patient with-
drew due to adverse effect in the NAC group. The adverse
effects were usually mild. The most common adverse
effects were constipation (16.1%), increased appetite (16.1%),Table 1 The number of patients taking concomitant
























0 2fatigue (12.9%), nervousness (12.9%), and daytime drowsi-
ness (12.9%) (Table 3).
Discussion
This randomized double-blind placebo-controlled clinical
trial showed that NAC as an adjuvant therapy more than
placebo decreased Irritability score in children with ASD.
This result suggests that oral NAC as a supplement may
be used in order to decrease the level of irritability in
children with autistic disorders. Considering the low
level of glutathione in autism [7], it is possible that NAC
may increase the production of glutathione and enhance
anti-oxidative stress system. Our results are in similar
line to a recently published case report [46] and a pilot
trial showed that NAC more than placebo decreased ir-
ritability in children with autism [47]. In addition, our
results are very similar to a previously published study
reported that NAC was tolerated well and there was no
serious adverse effect [47]. The study by Hardan et al., is
the only study reported that oral NAC is effective for
treating autism [47]. Their participants were taking con-
stant concomitant psychotropic medications and behav-
ioral interventions. However, the type and dosage of the
psychotropic medications were not reported. The most
common adverse effects of the previous study were con-
stipation, nausea, and diarrhea [47].
Limitation and future direction
The sample size was small and the duration of current
trial was very short. It is not clear whether the symptom
will relapse after the discontinuation of NAC. In addition,
it is not examined whether this effect will be stable in long
term. Further studies may investigate whether NAC en-
hances anti-oxidative stress system or NAC decreases
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Irritability N-Acetylcysteine + risperidone 13.2(5.3) 10.0(4.1) 9.7(4.1) F1,29= 4.9, P<0.035
Placebo+Risperidone 16.7(7.8) 15.5(7.9) 15.1(7.8)
Hyperactivity and Noncompliance N-Acetylcysteine + risperidone 29.3(6.4) 21.4(7.7) 18.3(6.9) F1,29= 2.4, P=0.12
Placebo+Risperidone 31.9(8.9) 26.8(11.0) 24.3(12.1)
Lethargy and Social Withdrawal N-Acetylcysteine + risperidone 11.9(6.5) 9.0(5.7) 8.5(6.5) F1,28= 0.4, P=0.53
Placebo+Risperidone 12.2(8.3) 11.0(7.8) 10.9(7.5)6
Stereotypic Behavior N-Acetylcysteine + risperidone 6.6(4.5) 4.5(3.6) 3.9(2.7) F1,28= 2.8, P=0.1
Placebo+Risperidone 8.5(6.3) 7.7(6.2) 7.8(6.6)
Inappropriate Speech N-Acetylcysteine + risperidone 3.9(3.7) 3.8(3.7) 3.2(3.4) F1,29= 1.8, P=0.1
Placebo+Risperidone 5.7(3.8) 5.3(3.7) 5.2(4.0)
Table 3 The number of patients with the adverse effects in the N-Acetylcysteine + risperidone group and
Placebo+risperidone group
Adverse effect N-Acetylcysteine + risperidone group Placebo+risperidone group
Number Percent Number Percent
Daytime drowsiness 4 12.9 2 6.5
Morning drowsiness 1 3.2 0 0
Stiffness 2 6.5 0 0
Slowed movement 2 6.5 0 0
Decreased Appetite 1 3.2 - 0
Fatigue 4 12.9 4 3.2
Constipation 5 16.1 1 3.2
Increased appetite 5 16.1 3 9.7
Decreased appetite 2 6.5 1 3.2
Diarrhea 0 0 1 3.2
Tremor 2 6.5 0 0
Abdominal pain 1 3.2 0 0
Nervousness 4 12.9 0 0
Itches 1 3.2 1 3.2
Restlessness 2 6.5 2 6.5
Twitches 1 3.2 0 0
Blurred vision 1 3.2 0 0
Urinary retention 0 0 0 0
Dizziness 0 0 0 0
Skin rash 0 0 0 0
Itches 0 0 0 0
Dry mouth 0 0 0 0
Swallowing difficulty 0 0 0 0
Seizure 0 0 0 0
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homogenous group, further studies should not include a
wide range of children. In addition, it is recommended to
assess the quality of life using other secondary measures
in further studies. Finally, the concomitant use of risperi-
done may limit the efficacy of obtained results. Therefore,
the efficacy of higher doses of NAC should be investigated
in further trials.
Conclusion
NAC+risperidone decreased irritability in this trial. This
improvement in the NAC+risperidone group was more
than that of the placebo+risperidone group. However,
NAC no more than placebo decreased other ABC sub-
scales scores including: Lethargy and Social Withdrawal,
Stereotypic Behavior, Hyperactivity and Noncompliance,
and Inappropriate Speech. Future trials with larger sample
sizes, longer durations, and higher doses are required in
order to examine the possible effects of NAC on autism.
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